Boehringer Ingelheim Pharmaceuticals, Inc.

Abdelhakim Hammach

Neil Moss

Daniel R Goldberg

Pier Francesco Cirillo

John R Regan

Hidenori Takahashi

Donghong Amy Gao

Victor Marc Kamhi

Mark Stephen Ralph

Daniel Kuzmich

Tina Marie Morwick

Roger John Snow

Anthony S Prokopowicz

David S Thomson

Ming-Hong Hao

Usha R Patel

Zhaoming Xiong

Matthew Russell Netherton

Ronald A Aungst, Jr

Kevin Chungeng Qian

John Robert Proudfoot

Renee M Zindell

Lifen Wu

Mario G Cardozo

Christopher Ronald Sarko

Thomas Martin Kirrane, Jr

Xiao-Jun Wang

Younes Bekkali

Pingrong Liu

Matt Aaron Tschantz

Gregory Paul Roth

Christopher Pargellis

Thomas Wai-Ho Lee

Paul S Riska

Robert D Selliah

Doris Riether

Hossein Razavi

Derek Cogan

Michael Jason Burke

Alan David Swinamer

Michel Jose Emmanuel

Rajashekhar Betageri

Ingo Andreas Mugge

Fariba Soleymanzadeh

Ji Wang

Joerg Bentzien

Jennifer A Kowalski

Christian Hanke Justus Joachim Harcken

Antonio J Barbosa

Antonio Jose Del Moral Barbosa, Jr

Andre White

Pier Francesco

Kristen Mueller

Ronald A Aungst

Compounds of Formula (IA), (IB), (IC), and (ID) wherein R, R, R, R, R, and Rare as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof

Compounds of Formula (IA) and (IB) wherein R, R, R, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Compounds of Formula (I) wherein R, R, R, R, R, R, and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Disclosed are amide compounds of formula (I): wherein Ar, Q, Y and R-Rof formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases

Disclosed are compounds of formula (I) Where Ar, X, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines and are thus useful for treating cytokine mediated diseases. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Triazole compounds

Disclosed are compounds of formula (I) Where Ar, X, Y, Q, W, R, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Disclosed are compounds of formula(I): wherein R, R, W and X of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Fluorinated di-aryl urea compounds

Disclosed are benzimidazolone compounds of formulas (I) & (II): wherein R, R, R, R, R, X, L, m, n and t are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds 

Heterocyclic compounds

Disclosed are 1,4-disubstituted benzo-fused urea compounds of formula (I):wherein Ar, X, A, L, and Q of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

1,4-benzofused urea compounds useful in treating cytokine mediated diseases

Disclosed are compounds of formula (I):wherein R, R, W and X of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Disclosed are compounds useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Compounds useful as anti-inflammatory agents

Disclosed are novel compounds of formula (I):wherein Ar, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

Heterocyclic compounds useful as inhibitors of tyrosine kinases

1,4-Disubstituted benzo-fused urea compounds

Growing community of inventors

Danbury, CT, United States of America

Abdelhakim Hammach